Data on Single Nucleotide Polymorphism of DNA Repair Genes and Breast Cancer Risk from Poland.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 12 07 2017
accepted: 29 11 2017
pubmed: 7 12 2017
medline: 31 3 2020
entrez: 7 12 2017
Statut: ppublish

Résumé

Single nucleotide polymorphisms (SNPs) may modify the risk of cancer. They may be then regarded as potential markers of carcinogenesis. The aim of this study was to analyze the frequency of genotypes and alleles of SNPs in DNA repair genes and to investigate the influence this genetic variation exerts on breast cancer in Polish females. The test group comprised 600 females with breast cancer and 600 healthy controls. Genomic DNA was isolated and the SNPs in DNA repair genes were determined by High-Resolution Melter (HRM) technique. Following polymorphisms were analysed: Arg399Gln (rs25487) of the XRCC1, Gly322Asp (rs4987188) of the hMSH2, Lys751Gln (rs13181) of the XPD, Arg188His (rs3218536) of the XRCC2, P871L (rs799917) of the BRCA1 and N372H (rs144848) of the BRCA2 gene. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each genotype and allele. Statistically significant correlations were identified between 4 single nucleotide polymorphisms and the breast cancer risk: rs25487 rs4987188 rs13181 and rs799917. The alleles XRCC1-Gln (OR 5.11; 95% CI 5.68-11.64, p < .0001), hMSH2-Asp (OR 4.66; 95% CI 3.90-5.56, p < .0001), XPD-Gln (OR 2.65; 95% CI 2.24-3.14, p < .0001) and BRCA1-L (OR 1.45; 95% CI 1.24-1.71, p < .0001) genes were strongly correlated with this malignancy. No correlation was found between the studied SNPs and tumor grading nor the lymph node status. Further research on larger groups is warranted to determine the influence of above-mentioned genetic variants on breast cancer risk.

Identifiants

pubmed: 29209986
doi: 10.1007/s12253-017-0370-8
pii: 10.1007/s12253-017-0370-8
doi:

Substances chimiques

Biomarkers, Tumor 0
DNA-Binding Proteins 0
X-ray Repair Cross Complementing Protein 1 0
XRCC1 protein, human 0
XRCC2 protein, human 0
DNA Repair Enzymes EC 6.5.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1311-1317

Références

Annu Rev Biochem. 2010;79:181-211
pubmed: 20192759
Int J Cancer. 2014 Feb 1;134(3):654-63
pubmed: 23852586
Clin Colon Rectal Surg. 2012 Jun;25(2):103-10
pubmed: 23730225
Hum Mutat. 2013 Mar;34(3):490-7
pubmed: 23255516
Ann Oncol. 2003;14 Suppl 5:v128-49
pubmed: 14684503
Cancer. 2015 Jan 1;121(1):8-16
pubmed: 25043972
PLoS One. 2014 Jan 27;9(1):e87259
pubmed: 24475258
Mutat Res. 2012 Jan 3;729(1-2):24-34
pubmed: 21945240
Nat Genet. 2001 Mar;27(3):247-54
pubmed: 11242102
Eur J Cancer. 2015 Oct;51(15):2242-2253
pubmed: 26421826
Nucleic Acids Res. 2007;35(22):7466-74
pubmed: 17913742
J Natl Cancer Inst. 2000 Jul 19;92(14):1126-35
pubmed: 10904085
Nature. 2009 Oct 22;461(7267):1071-8
pubmed: 19847258
Eur J Gynaecol Oncol. 2012;33(2):145-50
pubmed: 22611952
Cancer Causes Control. 2008 Dec;19(10):1077-83
pubmed: 18478337
Mayo Clin Proc. 2010 Dec;85(12):1111-20
pubmed: 21123638
Cancer Control. 2012 Oct;19(4):255-66
pubmed: 23037493
Carcinogenesis. 2009 Jan;30(1):2-10
pubmed: 18978338
World J Clin Oncol. 2011 Sep 10;2(9):329-38
pubmed: 21909479
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
Exp Ther Med. 2011 Nov;2(6):1193-1198
pubmed: 22977643
Am J Hum Genet. 2007 Dec;81(6):1186-200
pubmed: 17999359
Br J Cancer. 2004 May 17;90(10):2002-5
pubmed: 15138485
Tohoku J Exp Med. 2011;224(3):201-8
pubmed: 21701125
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Future Oncol. 2014 May;10(7):1215-37
pubmed: 24947262
Int J Biol Markers. 2017 Jul 24;32(3):e337-e343
pubmed: 28315507
Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60
pubmed: 11535547
Pathol Oncol Res. 2015 Sep;21(4):935-40
pubmed: 25743260
Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12213-7
pubmed: 7991608
Cell Res. 2008 Jan;18(1):99-113
pubmed: 18166982

Auteurs

Beata Smolarz (B)

Laboratory of Cancer Genetics, Department of Pathology, Institute of Polish Mother's Memorial Hospital, Rzgowska 281/289, 93-338, Lodz, Poland. smolbea@wp.pl.

Magdalena Bryś (M)

Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-237, Lodz, Poland.

Ewa Forma (E)

Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-237, Lodz, Poland.

Marek Zadrożny (M)

Department of Oncological Surgery and Breast Diseases, Polish Mother's Memorial Hospital - Research Institute, Rzgowska 281/289, 93-338, Lodz, Poland.

Jan Bieńkiewicz (J)

Department of Surgical and Endoscopic Gynecology and Gynecologic Oncology, Polish Mothers' Memorial Hospital-Research Institute, Rzgowska 281/289, 93-338, Lodz, Poland.

Hanna Romanowicz (H)

Laboratory of Cancer Genetics, Department of Pathology, Institute of Polish Mother's Memorial Hospital, Rzgowska 281/289, 93-338, Lodz, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH